• NeuroSense reported Phase 2b PARADIGM results showing its PrimeC ALS candidate met the trial’s primary endpoint.
• The study showed a treatment-linked reduction in a key ALS disease marker versus placebo, supporting evidence of target engagement.
• Management also pointed to consistent benefits across clinical outcomes and survival, reinforcing the case for a disease-modifying profile.
• Trial safety remained favorable over extended dosing, with no new safety signals reported.
• FDA clearance has been secured to start the global Phase 3 PARAGON study, shifting the program into confirmatory testing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-072907), on June 29, 2026, and is solely responsible for the information contained therein.